This finding, coupled with the fact that more than 50% of PDA cells lines with sustained Hh signaling activity are resistant to SMO antagonist cyclopamine [14], implicates alternative means of GLI regulation by KRAS and TGF-β in PDA [15], [19]. This evidence concerns the gene KRAS and Patent ductus arteriosus.